CIK 0001853921 · <br>Emerging growth company
Scribe Therapeutics, Inc.
Sign in to watch- Ticker
- SCTX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 822157847
- Phone
- 510-454-0213
- Business address
- 1150 MARINA VILLAGE PKWY, ALAMEDA, CA, 94501
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-28 | Aghazadeh Behzad Director | Purchase | +7,905 | $18.25 | $144K | 3,088,888 |
| 2026-07-27 | Doudna Jennifer A 10% owner | Conversion | +12,511 | 603,547 | ||
| 2026-07-27 | Doudna Jennifer A 10% owner | Conversion · Series A-1 Preferred Stock | −74,088 | 0 | ||
| 2026-07-27 | AH Bio Fund II, L.P. 10% owner | Conversion | +2,051,742 | 2,051,742 | ||
| 2026-07-27 | AH Bio Fund II, L.P. 10% owner | Conversion | +697,650 | 697,650 | ||
| 2026-07-27 | AH Bio Fund II, L.P. 10% owner | Purchase | +333,333 | $15.00 | $5.0M | 2,385,075 |
| 2026-07-27 | AH Bio Fund II, L.P. 10% owner | Conversion · Series A Preferred Stock | −12,150,003 | 0 | ||
| 2026-07-27 | AH Bio Fund II, L.P. 10% owner | Conversion · Series B Preferred Stock | −4,131,344 | 0 | ||
| 2026-07-27 | GORDON CARL L Director | Conversion | +348,825 | 348,825 | ||
| 2026-07-27 | GORDON CARL L Director | Purchase | +1,000,000 | $15.00 | $15.0M | 1,348,825 |
| 2026-07-27 | GORDON CARL L Director | Conversion · Series B Preferred Stock | −2,065,672 | 0 | ||
| 2026-07-27 | ORBIMED ADVISORS LLC Director | Conversion | +348,825 | 348,825 | ||
| 2026-07-27 | ORBIMED ADVISORS LLC Director | Purchase | +1,000,000 | $15.00 | $15.0M | 1,348,825 |
| 2026-07-27 | ORBIMED ADVISORS LLC Director | Conversion · Series B Preferred Stock | −2,065,672 | 0 | ||
| 2026-07-24 | Aghazadeh Behzad Director | Purchase | +2,333,333 | $15.00 | $35.0M | 3,030,983 |
| 2026-07-24 | Aghazadeh Behzad Director | Purchase | +50,000 | $22.31 | $1.1M | 3,080,983 |
| 2026-07-23 | Staahl Brett 10% owner | Grant or award · Stock Option (Right to Buy) | +19,385 | 19,385 | ||
| 2026-07-23 | Staahl Brett 10% owner | Grant or award · Performance-based Stock Option (Right to Buy) | +19,385 | 19,385 | ||
| 2026-07-23 | Watson James Dean Director | Grant or award · Stock Option (Right to Buy) | +14,725 | 14,725 | ||
| 2026-07-23 | Parrot David Chief Financial Officer | Purchase | +1,333 | $15.00 | $20K | 1,333 |
Page 1 of 2 · 35 trades